FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409545458> ?p ?o ?g. }

• W2409545458 endingPage "34" @default.
• W2409545458 startingPage "3624" @default.
• W2409545458 abstract "Our previous study showed that specifically delivering BikDD, a constitutive active mutant of pro-apoptotic protein Bik, to breast cancer cell xenografts in immunocompromised mice has a potent activity against tumor initiating cells (TICs), and that the combination between tyrosine kinase inhibitors (TKI) and BikDD gene therapy yielded synergistic effect on EGFR and HER2 positive breast cancer cells in immunodeficient nude mice. Those encouraging results have allowed us to propose a clinical trial using the liposome-complexing plasmid DNA expressing BikDD gene which has been approved by the NIH RAC Advisory committee. However, it is imperative to test whether systemic delivery of BikDD-expressing plasmid DNAs with liposomes into immunocompetent mice has therapeutic efficacy and tolerable side effects as what we observed in the nude mice model. In this study, we investigated the effects of BikDD gene-therapy on the primary mammary tumors, especially on tumor initiating cells (TICs), of a genetically engineered immunocompetent mouse harboring normal microenvironment and immune response. The effects on TIC population in tumors were determined by FACS analysis with different sets of murine specific TIC markers, CD49f(high)CD61(high) and CD24(+)Jagged1(-). First we showed in vitro that ectopic expression of BikDD in murine N202 cells derived from MMTV-HER2/Neu transgenic mouse tumors induced apoptosis and decreased the number of TICs. Consistently, systemic delivery of VISA-Claudin4-BikDD by liposome complexes significantly inhibited mammary tumor growth and slowed down residual tumor growth post cessation of therapy in MMTV-HER2/Neu transgenic mice compared to the controls. In addition, the anti-tumor effects of BikDD in vivo were consistent with decreased TIC population assessed by FACS analysis and in vitro tumorsphere formation assay of freshly isolated tumor cells. Importantly, systemic administration of BikDD did not cause significant cytotoxic response in standard toxicity assays or body weight changes. Taken together, our findings validated that selective expression of BikDD in the primary mammary tumors in immunocompetent hosts significantly reduced tumor burden and inhibited the residual tumor growth at off-therapy stage by eliminating TICs. Hence, the VISA-Claudin4-BikDD-mediated gene therapy is worthy of further investigation in breast cancer clinical trials." @default.
• W2409545458 created "2016-06-24" @default.
• W2409545458 creator A5005889039 @default.
• W2409545458 creator A5018650939 @default.
• W2409545458 creator A5021104158 @default.
• W2409545458 creator A5024055260 @default.
• W2409545458 creator A5045415378 @default.
• W2409545458 creator A5071293792 @default.
• W2409545458 creator A5080647721 @default.
• W2409545458 creator A5088712768 @default.
• W2409545458 date "2015-01-01" @default.
• W2409545458 modified "2023-10-16" @default.
• W2409545458 title "Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells." @default.
• W2409545458 cites W1976203623 @default.
• W2409545458 cites W1979440527 @default.
• W2409545458 cites W1982093899 @default.
• W2409545458 cites W2016884538 @default.
• W2409545458 cites W2016909614 @default.
• W2409545458 cites W2027102951 @default.
• W2409545458 cites W2044702943 @default.
• W2409545458 cites W2059854292 @default.
• W2409545458 cites W2073537725 @default.
• W2409545458 cites W2083274861 @default.
• W2409545458 cites W2086224272 @default.
• W2409545458 cites W2090229207 @default.
• W2409545458 cites W2095659509 @default.
• W2409545458 cites W2107921263 @default.
• W2409545458 cites W2108696990 @default.
• W2409545458 cites W2111688257 @default.
• W2409545458 cites W2115585914 @default.
• W2409545458 cites W2118143278 @default.
• W2409545458 cites W2127617517 @default.
• W2409545458 cites W2138094362 @default.
• W2409545458 cites W2140152239 @default.
• W2409545458 cites W2150488608 @default.
• W2409545458 cites W2155509815 @default.
• W2409545458 cites W2155667408 @default.
• W2409545458 cites W2159640574 @default.
• W2409545458 cites W2163292580 @default.
• W2409545458 cites W2171313040 @default.
• W2409545458 cites W2560367415 @default.
• W2409545458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4731636" @default.
• W2409545458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26885451" @default.
• W2409545458 hasPublicationYear "2015" @default.
• W2409545458 type Work @default.
• W2409545458 sameAs 2409545458 @default.
• W2409545458 citedByCount "1" @default.
• W2409545458 countsByYear W24095454582017 @default.
• W2409545458 crossrefType "journal-article" @default.
• W2409545458 hasAuthorship W2409545458A5005889039 @default.
• W2409545458 hasAuthorship W2409545458A5018650939 @default.
• W2409545458 hasAuthorship W2409545458A5021104158 @default.
• W2409545458 hasAuthorship W2409545458A5024055260 @default.
• W2409545458 hasAuthorship W2409545458A5045415378 @default.
• W2409545458 hasAuthorship W2409545458A5071293792 @default.
• W2409545458 hasAuthorship W2409545458A5080647721 @default.
• W2409545458 hasAuthorship W2409545458A5088712768 @default.
• W2409545458 hasConcept C102230213 @default.
• W2409545458 hasConcept C104317684 @default.
• W2409545458 hasConcept C111599444 @default.
• W2409545458 hasConcept C121608353 @default.
• W2409545458 hasConcept C126322002 @default.
• W2409545458 hasConcept C141035611 @default.
• W2409545458 hasConcept C190283241 @default.
• W2409545458 hasConcept C2776187077 @default.
• W2409545458 hasConcept C2908647359 @default.
• W2409545458 hasConcept C502942594 @default.
• W2409545458 hasConcept C530470458 @default.
• W2409545458 hasConcept C55493867 @default.
• W2409545458 hasConcept C71924100 @default.
• W2409545458 hasConcept C86803240 @default.
• W2409545458 hasConcept C99454951 @default.
• W2409545458 hasConceptScore W2409545458C102230213 @default.
• W2409545458 hasConceptScore W2409545458C104317684 @default.
• W2409545458 hasConceptScore W2409545458C111599444 @default.
• W2409545458 hasConceptScore W2409545458C121608353 @default.
• W2409545458 hasConceptScore W2409545458C126322002 @default.
• W2409545458 hasConceptScore W2409545458C141035611 @default.
• W2409545458 hasConceptScore W2409545458C190283241 @default.
• W2409545458 hasConceptScore W2409545458C2776187077 @default.
• W2409545458 hasConceptScore W2409545458C2908647359 @default.
• W2409545458 hasConceptScore W2409545458C502942594 @default.
• W2409545458 hasConceptScore W2409545458C530470458 @default.
• W2409545458 hasConceptScore W2409545458C55493867 @default.
• W2409545458 hasConceptScore W2409545458C71924100 @default.
• W2409545458 hasConceptScore W2409545458C86803240 @default.
• W2409545458 hasConceptScore W2409545458C99454951 @default.
• W2409545458 hasIssue "12" @default.
• W2409545458 hasLocation W24095454581 @default.
• W2409545458 hasOpenAccess W2409545458 @default.
• W2409545458 hasPrimaryLocation W24095454581 @default.
• W2409545458 hasRelatedWork W1488158769 @default.
• W2409545458 hasRelatedWork W1553968108 @default.
• W2409545458 hasRelatedWork W1600011088 @default.
• W2409545458 hasRelatedWork W1606064840 @default.
• W2409545458 hasRelatedWork W1992792239 @default.
• W2409545458 hasRelatedWork W2004958669 @default.
• W2409545458 hasRelatedWork W2081440216 @default.

• next